Kura Oncology, Inc. (KURA) Stock

Kura Oncology, Inc. (KURA) is a Healthcare stock trading at $9.89 (as of 2026-06-18), with a market capitalization of $905.50M and a trailing P/E of -3.0. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company developing small-molecule medicines for cancer. Its pipeline includes ziftomenib for genetically defined subsets of acute leukemias and tipifarnib for solid tumors and hematologic indications, and it has a clinical collaboration with Novartis to study tipifarnib with alpelisib in head and neck squamous cell carcinoma.

Valuation — source: SEC EDGAR (first-party)
Price	$9.89
Market Cap	$905.50M
P/E Ratio	-3.0
EV / EBITDA	-2.7
Price / Book	8.17
Price / Sales	12.31
DCF Value (model)	$-12.05
DCF Upside vs Price	-221.8%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$67.48M
Net Margin	-412.9%
Return on Equity	-273.0%
Debt / Equity	0.09
Current Ratio	6.15
Revenue Growth (YoY)	25.2%
EPS Growth (YoY)	57.4%
FCF Growth (YoY)	-152.8%

Financial Health — source: SEC EDGAR
Altman Z-Score	-1.60 (distress)

Valuation vs Sector & Industry
Stock P/E	-3.0
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-114.1%
vs Industry	-117.2%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	BlackRock, Inc. ($78.35M)
Institutional Holders Tracked	10
Congressional Trades (recent)	1

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Troy Edward Wilson
Employees	192
Country	US
IPO Date	2015-09-16

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.